信立泰(002294.SZ)：SAL0139药品临床试验申请获受理

Core Viewpoint - The company has received approval from the National Medical Products Administration for the clinical trial application of its innovative small molecule drug SAL0139, which is intended for the treatment of hyperlipidemia [1] Group 1 - The drug SAL0139 is developed by the company and possesses independent intellectual property rights [1] - The application submitted by the company is specifically for conducting clinical trials of SAL0139 for hyperlipidemia treatment [1]